Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Debt to Equity (2017 - 2021)

Sunshine Biopharma filings provide 5 years of Debt to Equity readings, the most recent being $8.98 for Q4 2021.

  • On a quarterly basis, Debt to Equity rose 1003.17% to $8.98 in Q4 2021 year-over-year; TTM through Dec 2021 was $8.98, a 1003.17% increase, with the full-year FY2021 number at $8.98, up 1003.17% from a year prior.
  • Debt to Equity hit $8.98 in Q4 2021 for Sunshine Biopharma, up from -$2.73 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $8.98 in Q4 2021 to a low of -$5.57 in Q4 2018.
  • Median Debt to Equity over the past 5 years was -$0.64 (2020), compared with a mean of -$0.02.
  • Biggest five-year swings in Debt to Equity: crashed 3908.81% in 2018 and later surged 1003.17% in 2021.
  • Sunshine Biopharma's Debt to Equity stood at -$0.14 in 2017, then plummeted by 3908.81% to -$5.57 in 2018, then skyrocketed by 99.33% to -$0.04 in 2019, then plummeted by 2580.8% to -$0.99 in 2020, then skyrocketed by 1003.17% to $8.98 in 2021.
  • The last three reported values for Debt to Equity were $8.98 (Q4 2021), -$2.73 (Q3 2021), and -$2.35 (Q2 2021) per Business Quant data.